Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

Hagop M. Kantarjian, Jorge Cortes, Susan O'Brien, Francis J. Giles, Maher Albitar, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia-Manero, Deborah A. Thomas, Debra Resta, Moshe Talpaz

Research output: Contribution to journalArticle

Abstract

Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph+ below 35%, and 4 minor [Ph+, 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P = .001), longer median survival (7 versus 4 months, P = .04), and lower 4-week induction mortality (4% versus 15%, P = .07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.

Original languageEnglish (US)
Pages (from-to)3547-3553
Number of pages7
JournalBlood
Volume99
Issue number10
DOIs
StatePublished - May 15 2002
Externally publishedYes

Fingerprint

Blast Crisis
Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes
Survival
Cytarabine
Therapeutics
bcr-abl Fusion Proteins
abl Genes
Salvaging
Salvage Therapy
Signal transduction
Poisons
Cytogenetics
Imatinib Mesylate
Signal Transduction
Genes
Control Groups
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kantarjian, H. M., Cortes, J., O'Brien, S., Giles, F. J., Albitar, M., Rios, M. B., ... Talpaz, M. (2002). Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 99(10), 3547-3553. https://doi.org/10.1182/blood.V99.10.3547

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. / Kantarjian, Hagop M.; Cortes, Jorge; O'Brien, Susan; Giles, Francis J.; Albitar, Maher; Rios, Mary Beth; Shan, Jianqin; Faderl, Stefan; Garcia-Manero, Guillermo; Thomas, Deborah A.; Resta, Debra; Talpaz, Moshe.

In: Blood, Vol. 99, No. 10, 15.05.2002, p. 3547-3553.

Research output: Contribution to journalArticle

Kantarjian, HM, Cortes, J, O'Brien, S, Giles, FJ, Albitar, M, Rios, MB, Shan, J, Faderl, S, Garcia-Manero, G, Thomas, DA, Resta, D & Talpaz, M 2002, 'Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase', Blood, vol. 99, no. 10, pp. 3547-3553. https://doi.org/10.1182/blood.V99.10.3547
Kantarjian, Hagop M. ; Cortes, Jorge ; O'Brien, Susan ; Giles, Francis J. ; Albitar, Maher ; Rios, Mary Beth ; Shan, Jianqin ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Thomas, Deborah A. ; Resta, Debra ; Talpaz, Moshe. / Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. In: Blood. 2002 ; Vol. 99, No. 10. pp. 3547-3553.
@article{25eacdbcc09740d8922b6be997aa2b0e,
title = "Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase",
abstract = "Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52{\%} (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16{\%} (12 patients: 5 complete, 3 partial [Ph+ below 35{\%}, and 4 minor [Ph+, 34{\%} to 90{\%}]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22{\%}. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55{\%} versus 29{\%}, P = .001), longer median survival (7 versus 4 months, P = .04), and lower 4-week induction mortality (4{\%} versus 15{\%}, P = .07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.",
author = "Kantarjian, {Hagop M.} and Jorge Cortes and Susan O'Brien and Giles, {Francis J.} and Maher Albitar and Rios, {Mary Beth} and Jianqin Shan and Stefan Faderl and Guillermo Garcia-Manero and Thomas, {Deborah A.} and Debra Resta and Moshe Talpaz",
year = "2002",
month = "5",
day = "15",
doi = "10.1182/blood.V99.10.3547",
language = "English (US)",
volume = "99",
pages = "3547--3553",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Giles, Francis J.

AU - Albitar, Maher

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Thomas, Deborah A.

AU - Resta, Debra

AU - Talpaz, Moshe

PY - 2002/5/15

Y1 - 2002/5/15

N2 - Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph+ below 35%, and 4 minor [Ph+, 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P = .001), longer median survival (7 versus 4 months, P = .04), and lower 4-week induction mortality (4% versus 15%, P = .07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.

AB - Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph+ below 35%, and 4 minor [Ph+, 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P = .001), longer median survival (7 versus 4 months, P = .04), and lower 4-week induction mortality (4% versus 15%, P = .07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.

UR - http://www.scopus.com/inward/record.url?scp=0037092980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037092980&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.10.3547

DO - 10.1182/blood.V99.10.3547

M3 - Article

C2 - 11986206

AN - SCOPUS:0037092980

VL - 99

SP - 3547

EP - 3553

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -